Physician profile
Stephen L Davidson
NPI 1902852171
$4,188.14
in general payments reported to CMS, 2019-2025
46 companies · $573 in 2025
The $573 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $91.10 · 2021: $452 · 2022: $681 · 2023: $754 · 2024: $949 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $515.03 | 2019-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $419.41 | 2019-2025 | |
| Pfizer INC. | $341.36 | 2019-2025 | |
| Exelixis INC. | $235.93 | 2019-2022 | |
| Janssen Biotech, INC. | $191.31 | 2019-2024 | Erleada, Tecvayli, Darzalex |
| Genentech USA, INC. | $187.04 | 2019-2021 | |
| Abbvie INC. | $185.96 | 2022-2025 | Venclexta |
| Beigene USA, INC. | $164.92 | 2021-2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $146.79 | 2019-2025 | Padcev, Xospata, Vyloy |
| Merck Sharp & Dohme LLC | $133.59 | 2019-2024 | Keytruda |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Gilead Sciences, INC. | $127.62 | 2021-2025 | Trodelvy |
| Eisai INC. | $107.79 | 2021-2023 | |
| Glaxosmithkline, LLC. | $102.73 | 2020-2025 | Jemperli, Ojjaara, Blenrep |
| Array Biopharma INC | $97.95 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.